Polymer delivery systems for long-acting antiretroviral drugs

Mohammad Ullah Nayan; Sudipta Panja; Ashrafi Sultana; Lubaba A. Zaman; Lalitkumar K. Vora; Brady Sillman; Howard E. Gendelman; Benson Edagwa

doi:10.3390/pharmaceutics16020183

Polymer delivery systems for long-acting antiretroviral drugs

Mohammad Ullah Nayan, Sudipta Panja, Ashrafi Sultana, Lubaba A. Zaman, Lalitkumar K. Vora, Brady Sillman, Howard E. Gendelman^*, Benson Edagwa^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

41 Downloads (Pure)

Abstract

The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

Original language	English
Article number	183
Number of pages	41
Journal	Pharmaceutics
Volume	16
Issue number	2
Early online date	28 Jan 2024
DOIs	https://doi.org/10.3390/pharmaceutics16020183
Publication status	Published - Feb 2024

Bibliographical note

Funding Information:
The work is supported by National Institutes of Health grants R01 NS034239; R01 NS036126; R01 MH115860; R01 NS126089; T32NS105594 (HEG); R01 AI145542 (BE and HEG); R01 AI158160 (HEG and BE).

Publisher Copyright:
© 2024 by the authors.

Keywords

antiretroviral therapy
chronic infectious diseases
HIV
implants
long-acting formulations
microarray patches
polymer
prodrug nanoformulations
vaginal rings

ASJC Scopus subject areas

Pharmaceutical Science

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/pharmaceutics16020183Licence: CC BY

Polymer delivery systems for long-acting antiretroviral drugs
Copyright 2024 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 6.14 MBLicence: CC BY

Cite this

@article{7f84bae949104e07bc7bf7bed1ed7f07,

title = "Polymer delivery systems for long-acting antiretroviral drugs",

abstract = "The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients{\textquoteright} needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.",

keywords = "antiretroviral therapy, chronic infectious diseases, HIV, implants, long-acting formulations, microarray patches, polymer, prodrug nanoformulations, vaginal rings",

author = "Nayan, {Mohammad Ullah} and Sudipta Panja and Ashrafi Sultana and Zaman, {Lubaba A.} and Vora, {Lalitkumar K.} and Brady Sillman and Gendelman, {Howard E.} and Benson Edagwa",

note = "Funding Information: The work is supported by National Institutes of Health grants R01 NS034239; R01 NS036126; R01 MH115860; R01 NS126089; T32NS105594 (HEG); R01 AI145542 (BE and HEG); R01 AI158160 (HEG and BE). Publisher Copyright: {\textcopyright} 2024 by the authors.",

year = "2024",

month = feb,

doi = "10.3390/pharmaceutics16020183",

language = "English",

volume = "16",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI",

number = "2",

}

TY - JOUR

T1 - Polymer delivery systems for long-acting antiretroviral drugs

AU - Nayan, Mohammad Ullah

AU - Panja, Sudipta

AU - Sultana, Ashrafi

AU - Zaman, Lubaba A.

AU - Vora, Lalitkumar K.

AU - Sillman, Brady

AU - Gendelman, Howard E.

AU - Edagwa, Benson

N1 - Funding Information: The work is supported by National Institutes of Health grants R01 NS034239; R01 NS036126; R01 MH115860; R01 NS126089; T32NS105594 (HEG); R01 AI145542 (BE and HEG); R01 AI158160 (HEG and BE). Publisher Copyright: © 2024 by the authors.

PY - 2024/2

Y1 - 2024/2

N2 - The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

AB - The success of long-acting (LA) drug delivery systems (DDSs) is linked to their biocompatible polymers. These are used for extended therapeutic release. For treatment or prevention of human immune deficiency virus type one (HIV-1) infection, LA DDSs hold promise for improved regimen adherence and reduced toxicities. Current examples include Cabenuva, Apretude, and Sunlenca. Each is safe and effective. Alternative promising DDSs include implants, prodrugs, vaginal rings, and microarray patches. Each can further meet patients’ needs. We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

KW - antiretroviral therapy

KW - chronic infectious diseases

KW - HIV

KW - implants

KW - long-acting formulations

KW - microarray patches

KW - polymer

KW - prodrug nanoformulations

KW - vaginal rings

U2 - 10.3390/pharmaceutics16020183

DO - 10.3390/pharmaceutics16020183

M3 - Review article

AN - SCOPUS:85185950918

SN - 1999-4923

VL - 16

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 183

ER -

Polymer delivery systems for long-acting antiretroviral drugs

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this